R. S. Al-awar

This study identifies DNA-PK as a synthetic lethal target in TP53-deficient SHH medulloblastoma, showing that inhibiting DNA-PK enhances radiosensitivity and improves survival in preclinical models.

The paper identifies first-in-class inhibitors (BLUEs) that selectively inhibit BRISC complex activity by stabilizing an autoinhibited dimer, reducing interferon-stimulated gene expression.